While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.
|Original language||English (US)|
|Number of pages||7|
|State||Published - 2001|
ASJC Scopus subject areas
- Obstetrics and Gynecology